Menu
Not yet recruiting NCT06939400

Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

— Observational Glioblastoma Multiforme (GBM)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Photodynamic therapy (PDT), GBM patients recevied traditional treatment options.
Who it may be relevant to
Registry conditions: Glioblastoma Multiforme (GBM). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Overview

GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Interventions

  • Procedure Photodynamic therapy (PDT)
    GBM patients recevied surgical combination photodynamic therapy
  • Procedure GBM patients recevied traditional treatment options
    GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)

Primary outcome measures

  • Number of Participants with Treatment of Surgical combination Photodyanmic therapy [Time frame: From June 2025 to June 2027]

Eligibility criteria

Inclusion criteria

Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.

Exclusion criteria

  • Photosensitizer allergy.
  • Severe coagulation disorder.
  • Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
  • Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.

Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

China · 1 center
  • Zhejiang Provincial People's Hospital — Hangzhou

Identifiers

NCT: NCT06939400 · KY2024208

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗